



A Pilot Trial of Galcanezumab for Vestibular Migraine

[Clinicaltrials.gov/ct2/show/NCT04417361](https://clinicaltrials.gov/ct2/show/NCT04417361)

We're looking for adults 18-75 years old who are diagnosed with definite or probable vestibular migraine per Bárány Society criteria to examine the effectiveness of a new FDA-approved calcitonin gene-related peptide (CGRP) antagonist drug called galcanezumab (Emgality).

Vestibular migraine is a distinct subtype of migraine that causes episodic vertigo/dizziness. To date, there have been no randomized clinical trials comparing a drug to placebo for treating vestibular migraine.

Participants will be asked to:

- Attend 4 in-clinic study visits over 120 days
- Self-administer injections of galcanezumab or placebo at Day 30, Day 60, Day 90
- Respond to daily text messages asking about dizziness symptoms
- Fill out questionnaires at each study visit

Participants will receive:

- A \$100 prepaid American Express card at the second and fourth study visits (total \$200)

This study is supported by Eli Lilly & Co.

Location

- All 4 study visits will be at the UCSF Mount Zion Otolaryngology or Neurology Clinics

Are you eligible?

- Age 18-75 years old at first study visit
- Diagnosis with vestibular migraine
- Access to email and cell phone
- Fluency in English
- No prior or current treatment with a CGRP medication
- Not pregnant or breastfeeding
- No prior ear surgery
- No other vestibular diagnosis
- No allergies to galcanezumab
- No failure of treatment with more than 4 migraine prophylactic medications

Please contact a member of our study team with any questions:

- Study Coordinator
 - Adam Gardi
 - adam.gardi@ucsf.edu
- Principal Investigator
 - Dr. Jeffrey Sharon
 - jeffrey.sharon@ucsf.edu